
Publishers page: http://dx.doi.org/10.1038/s41380-020-0689-5 <http://dx.doi.org/10.1038/s41380-020-0689-5>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.
Association of polygenic score for major depression with response to lithium in patients with bipolar disorder

Azmeraw T. Amare 1,2 et al.

Abstract
Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap between depression and bipolar disorder, we investigated whether a polygenic susceptibility to major depression is associated with response to lithium treatment in patients with BD. Weighted polygenic scores (PGSs) were computed for major depression (MD) at different GWAS p value thresholds using genetic data obtained from 2586 bipolar patients who received lithium treatment and took part in the Consortium on Lithium Genetics (ConLi+Gen) study. Summary statistics from genome-wide association studies in MD (135,458 cases and 344,901 controls) from the Psychiatric Genomics Consortium (PGC) were used for PGS weighting. Response to lithium treatment was defined by continuous scores and categorical outcome (responders versus non-responders) using measurements on the Alda scale. Associations between PGSs of MD and lithium treatment response were assessed using a linear and binary logistic regression modeling for the continuous and categorical outcomes, respectively. The analysis was performed for the entire cohort, and for European and Asian sub-samples. The PGSs for MD were significantly associated with lithium treatment response in multi-ethnic, European or Asian populations, at various p value thresholds. Bipolar patients with a low polygenic load for MD were more likely to respond well to lithium, compared to those patients with high polygenic load [lowest vs highest PGS quartiles, multi-ethnic sample: OR = 1.54 (95% CI: 1.18–2.01) and European sample: OR = 1.75 (95% CI: 1.30–2.36)]. While our analysis in the Asian sample found equivalent effect size in the same direction: OR = 1.71 (95% CI: 0.61–4.90), this was not statistically significant. Using PGS decile comparison, we found a similar trend of association between a high genetic loading for MD and lower response to lithium. Our findings underscore the genetic contribution to lithium response in BD and support the emerging concept of a lithium-responsive biotype in BD.

Introduction
Bipolar disorder (BD) is a chronic and severe psychiatric illness characterized by episodic, abnormal manic and depressive mood states. An estimated 48.8 million people are affected by BD globally [1]. The disorder accounts for 9.9 million years of life lived with disability worldwide, and substantially increases all-cause mortality and risk of suicide [1, 2]. Amongst available treatment options, lithium is regarded as a gold standard by several clinical guidelines [3, 4]. Lithium uniquely protects against both manic and depressive illness phases, has demonstrated protective effects against suicide [5–7], and is particularly effective in preventing rehospitalization [8]. However, not all patients with BD fully benefit from lithium and only about 30% show full response to the drug [5–7]. In current psychiatric practice, no biological or clinical markers exist that could reliably predict responsiveness to lithium [9], and prescribing cannot be targeted to patients who benefit most while avoiding side effects and sub-optimal treatment for poor responders [10–13].

In order to develop objective response markers and to move forward towards personalized prescribing of lithium for BD patients, a better understanding of the biological mechanisms underlying lithium response is urgently required. Recent genome-wide association studies (GWAS) carried out by our International Consortium on Lithium Genetics (ConLi+Gen) [5] and others [14, 15] have indicated that genetic variation could be an important mediator of response to long-term lithium treatment response in BD patients. In addition, we have recently demonstrated that high genetic loading for schizophrenia (SCZ) risk variants in people with BD decreases the likelihood of favorable response to
lithium [16], suggesting that polygenic score (PGS) analysis of mental and physical traits could yield important information on the genetic architecture of BD phenotypes [17–19].

BD and MD show 47% genetic overlap [20–22], and shared risk genes and biological pathways have been described [21, 23, 24]. Lithium can be effective as an augmentation strategy in MD patients who have experienced an insufficient response to first-line antidepressants [25, 26] and is protective against further MD episodes after symptom remission has been achieved [27]. Moreover, a large observational study based on the Finnish registry showed that lithium is the most effective agent preventing rehospitalization in MD [27].

On the other hand, in BD, lithium is more effective in preventing manic than depressive episodes [28, 29], leading to the notion that better lithium responders might be more likely to experience manic predominant polarity, as opposed to depressive predominant polarity [30]. In support of this view, one study found that excellent lithium responders were characterized by a manic but not depressive polarity of the index episode [31]. Another study described an episodic illness pattern of ‘mania-depression-interval’ as a predictor for a good response, whereas a ‘depression-mania-interval’ predicted poorer outcomes [32]. Inter-episode residual mood symptoms, as opposed to full remission [6, 7, 33], a rapid cycling pattern [32, 33], and a history of mixed episodes [34, 35] have also been described as predictors of poor response. On the background of these complex interactions between BD, MD, and lithium treatment, we asked whether BD patients with a high genetic susceptibility for major depression, expressed by their PGS, would respond better or worse to lithium than BD patients with a low genetic loading [36].

Methods and materials
Discovery GWAS summary dataset
The polygenic score for this study was computed using individual genetic data from the International Consortium on Lithium Genetics (ConLi +Gen) [5], and GWAS summary statistics for MD from the Psychiatric Genomics Consortium (PGC) [36].

The summary GWAS for MD was produced from a meta-analysis of 9.6 million SNPs (PGC; http://www.med.unc.edu/pgc/), obtained from 7 cohorts (deCODE, Generation Scotland, GERA, iPSYCH, UK Biobank, PGC29 and 23andMe) containing 135,458 MD cases and 344,901 healthy controls [36].

Target study sample
For the PGS analysis, clinical data on lithium treatment response and genetic information were obtained from the International Consortium on Lithium Genetics (ConLi +Gen; www.ConLiGen.org) for n=2586 patients, including 23 patients in the replication sample [3, 5, 16]. A series of quality control procedures were implemented on the genotype data before and after imputation as described below.

Target outcome
Lithium treatment response was assessed using the validated “Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder” scale, also known as the Alda scale [7, 37, 38]. This scale quantifies symptom improvement over the course of treatment (A score, range 0–10), which is then weighted against five criteria (B score) that assess the quality of evidence for the response score [5], to arrive at a total Alda score. For dichotomized assessment of treatment response, patients with a total score of 7 or higher were categorized as “good responders”, and the remainder were categorized as poor responders [5, 38]. For continuous assessment of treatment response, Alda A scores were used [39]. In addition to the Alda scale scores, information on covariates such as age and gender was collected, as described in detail elsewhere [5].

Genotyping and quality control
The genome-wide genotypes, as well as clinical and demographic data, were collected by 22 participating sites. Quality control (QC) procedures were implemented on the genotype data using PLINK, version 1.09 prior to imputation [40]. Samples with low genotype rates <95%, sex inconsistencies (based on X-chromosome heterozygosity), and one of a pair of genetically related individuals were excluded. SNPs were excluded based on the following criteria: a poor genotyping rate (<95%), strand ambiguity (A/T and C/G SNPs), a low minor allele frequency (MAF < 1%), or those deviated from genotype frequency expectations under the Hardy–Weinberg Equilibrium (p < 10−6).

Imputation
The genotype data passing QC were imputed on the Michigan server [41] (https://imputationserver.sph.umich.edu) separately for each genotype platform using reference data from the 1000 Genomes Project Phase 3 (Version 5). The European reference panel was used for all the samples except for those from Japan and Taiwan, for which an East Asian reference population data was used. After excluding low-frequency SNPs (MAF < 10%); low-quality variants (imputation INFO < 0.9); and indels, the imputed dosages were converted to best-guess genotypes. The subsequent polygenic analyses were performed using these best-guess genotypes.

Statistical analyses
Polygenic score (PGS) association analysis PGSs were calculated using the approach previously described by the International Schizophrenia Consortium [42]. Prior to the PGS computation, independent SNPs were identified through a clumping procedure. Quality controlled SNPs were clumped for linkage disequilibrium based on GWAS association p value informed clumping at r² = 0.1 within a 250 kilobase window to create an SNPset in linkage equilibrium using PLINK software, version 1.09 run on Linux (plink --clump-p1 1 --clump-p2 1 --clump-r2 0.1 --clump-kb 250). PGSs of MD were calculated for each patient in the ConLi+Gen sample at ten p value thresholds (<1 × 10−4, <1×10−3, <0.01, <0.05, <0.1, <0.2, <0.3, <0.4, <0.5, <1). For a patient, a PGS was calculated at each p value threshold (PT) as the sum of allelic counts (from 0 to 2) for the reference alleles across independent SNPs on a genome-wide scale weighted by their effect sizes estimated as beta or log10 (odds ratio), obtained from previously published GWASs of MD [36]. Once the PGSs were constructed, a binary logistic regression model was applied for the binary outcome (lithium response versus non-response) and a linear regression modeling was implemented for the continuous outcome (Alda score on subscale A) to evaluate the association of the PGSs for MD with lithium treatment response at each PT. Using the PGS at the most optimal thresholds, we divided the study samples into quartiles and deciles, ranging from the lowest polygenic load (1st quartile or 1st decile) to the highest polygenic load (4th quartile or 10th decile). Then, we compared BP patients in the lower polygenic load quartiles (1st–3rd quartiles or 1st–9th deciles) with patients in the highest polygenic load quartile (4th quartile or 10th decile), to quantify the effect of MD polygenic load on lithium treatment response. The analysis was performed for the European sample (N = 2366), Asian sample (N = 220) and all the sample combined (N = 2586). Associations were considered significant at p < 0.05 after adjusting for covariates.

The PGS association analyses were adjusted for the covariates age, gender, genotyping platform, a polygenic score for schizophrenia [16], a polygenic score for bipolar disorder [43], and seven principal components (PCs) in the combined sample or five PCs in the European sample or four PCs in the Asian sample. The PCs were computed using a --pca command in PLINK and then the top PCs with an eigenvalue of >2.0 were extracted and used as covariates to correct for population stratification. The analyses were performed using R for Statistical Computing and PLINK, version 1.09 for Linux [40]. Prediction accuracy, the percentage of variance in lithium response accounted for by the PGS at each PT, was estimated as the variance explained by the full model including each PGS and covariates minus the variance explained by the model including only covariates.
Sensitivity analysis
To evaluate the robustness of our findings, we ran sensitivity analyses using GWAS summary data from bone traits [lumbar spine bone mineral density, femoral neck mineral density and forearm bone mineral density] [44] that have previously shown nonsignificant genetic correlations with psychiatric disorders [45]. Once we compute polygenic scores for lumbar spine bone mineral density, femoral neck mineral density and forearm bone mineral density, we evaluated its association with lithium treatment response, both continuous and categorical outcomes, in the combined sample (N = 2586). Each analysis was adjusted for covariates age, gender, genotyping platform, polygenic score for schizophrenia [16], polygenic score for bipolar disorder [43] and seven PCs.

Results
Sample characteristics and lithium treatment response rate After QC, 2586 patients (3193 before QC) remained for analysis. While n = 2366 were of European ancestry, the remaining (n = 220) were of Asian ancestry. In all, 704 patients (27.2%) responded optimally to lithium treatment (total Alda score ≥7). Detailed sample and demographics details have been described previously [16]. Analysis of the correlation between the PGSs for MD and the self reported number of depressive episodes available for a subset of the ConLi+Gen sample (N = 1140) showed a statistically significant positive correlation, with estimates ranging from 0.08 to 0.12, suggesting that the PGS for MD may be an approximation to a more severe depressive phenotype in BD (Supplementary Fig. 1).

The polygenic score for MD is inversely associated with lithium treatment response in BD

Statistically significant associations were found at various p value thresholds between the PGSs for MD and lithium treatment response. In the combined multi-ethnic sample, the strongest association were found at PT < 5 × 10−2; p < 0.001, R2 = 0.8% with the continuous outcome (Alda A score) and p < 0.001, R2 = 0.7% with the categorical outcome (total Alda score ≥7) (Fig. 1a).

In European ancestry patients, the PGS at most of the tested p value thresholds showed significant associations of MD PGS with lithium response across continuous and dichotomized outcomes. Strongest associations were found at PT < 5 × 10−2; p < 0.001, R2 = 0.7% with the continuous outcome and p < 0.001, R2 = 0.9% with the categorical outcome (Fig. 1b). However, in the Asian subsample, the association of the PGS for MD and lithium treatment response was less robust and marginal associations were found only with the continuous outcome at PT < 1 × 10−2 (p = 0.034, R2 = 0.85%) and PT < 5 × 10−2 (p = 0.042, R2 = 0.75%) (Fig. 1c). Using PRSice2 software, we found consistent results of association between the PGSs for MD and lithium treatment response [46] (Supplementary Fig. 2A–C). After adjusting for multiple testing using the Bonferroni method [47], associations remained statistically significant in the multi-ethnic and European sample, but not in the Asian sample (Supplementary Table 1). Beta coefficients for all associations were negative, indicating that high genetic loadings for MD are associated with poorer response to lithium in BD.

To further evaluate the impact of MD PGS on lithium treatment response, we divided the study population into quartiles and deciles based on their polygenic loading for MD. As shown in Fig. 2 and Table 1, BD patients who carry a lower polygenic load (1st quartile or 1st decile) for MD have higher odds of favorable lithium treatment response, compared to patients carrying a high polygenic load (4th quartile or 10th decile). In the combined sample, the odds ratio (OR) of favorable response for patients in the 1st quartile compared with those in the 4th quartile was 1.54 (95% CI: 1.18–2.01) and the OR of patients in 1st decile compared to the 10th decile was 1.49 (95% CI: 0.97–2.31). Stratified analysis by ethnicity found a stronger association in the European sample than the Asian sample (Table 1, Fig. 2 & Supplementary Fig. 3).

Sensitivity analysis
To ensure the robustness of our findings, we performed a sensitivity analysis and found no significant association between the polygenic scores for lumbar spine bone mineral density, femoral neck mineral density or forearm bone mineral density and lithium treatment response in bipolar patients, p > 0.05 for all polygenic score association tests at different p value thresholds (Supplementary Fig. 4A–C).

Discussion
Our study represents the first direct molecular evidence of an association between a genetic predisposition for major depression and poorer response to lithium treatment in patients with BD. Using PGS analyses of genetic variants related to MD, we found that BD patients with low genetic loading for these variants were about 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to BD patients with high MD genetic loading. Higher MD PGSs were associated with a higher number of reported life-time depressive episodes. Analyses following stratification of our sample into European and Asian ancestries indicated that these associations were particularly robust in the European subsample. Adjustment for the potential effects of psychiatric traits that show genetic overlap with MD (SCZ, BD), and sensitivity analyses with medical traits that are unrelated to psychiatric disorders [44] underscored the overall robustness of our findings. Our findings could form part of a genetic explanation for the previously described clinical observations in relation to mania, depression and lithium response in BD [6, 7, 28–35] and supports the notion that better lithium responsiveness could be associated with a ‘core’ bipolar phenotype in the Kraepelinian form of manic depression [35, 48], characterized by a predominant mania-depression-interval (MDI) sequence pattern [49, 50]. The fact that such a phenotype is complex and difficult to clinically identify is exemplified by the lack of meta-analytic evidence for a more straightforward association between lithium response and mania over depression dominance in BD [50].

Similarly, previous family studies found no association between a family psychiatric history of MD and poorer lithium response in BD [51]. Together with the previously reported inverse association of lithium response and schizophrenia PGS [16], in the same cohort, our finding suggests that the presence of psychiatric co-morbid genetic traits in BD diminishes the likelihood of optimal treatment response to lithium. Given the substantial overlap between schizophrenia- and MD risk alleles [43], the possibility that these effects are driven by similar molecular mechanisms warrants further clarification in future studies.
In addition to its effects in BD, lithium’s effectiveness as an adjunct antidepressant treatment for people with treatment resistant MD is well established [52–58], and lithium is a first line treatment for BD type 2 that shows a substantial genetic overlap with MD [59]. Therefore, our finding raises the intriguing possibility that lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in BD.
Our finding of a more robust effect of the MD PGS association with lithium response in European compared to Asian patients is interesting but needs to be interpreted with caution. First, our Asian subsample was small (n = 220) and may not have been powered sufficiently to detect more consistent effects. Second, the polygenic basis of MD in East Asian and European populations is only partially shared with reported trans-ancestry genetic correlation of 0.33–0.41 [60]. The projection of MD risk alleles obtained from the global PGC study onto the Asian ConLi+Gen cohort for PGS analysis may, therefore, be less precise and underestimate the true MD PGS effect. It is notable that ethnic differences with regards to lithium response have not been studied extensively and are not supported by a smaller previous study [61].

The main limitation of our study is that PGSs for MD explain only a small proportion of the variance in lithium treatment response (<1%), and on their own have no utility as clinical tests. However, since we detected significant effects in our relatively small sample, it is likely that in the future...
increased sample sizes will further improve the predictive power of PGSs [62]. Further, the current version of the Alda scale assesses only overall lithium efficacy but not effects specific to predominant illness polarity or episode sequence pattern. Availability and incorporation of such information would have refined our results. While our findings, in isolation, are not yet ripe for clinical applications, they could serve as a component of multimodal prediction models incorporating clinical and other biological data. The development of such models and the demonstration of their potential clinical utility in prospective study designs are beyond the scope of the current investigation but need to be attempted to translate our research findings into actionable clinical applications.

In conclusion, we demonstrated that high genetic loadings for MD are predictive of unfavorable long-term response to lithium in patients with BD. Our study underscores the potential of PGS analysis to contribute to predictive models for medication response in psychiatry. The results of our study support clinical observations that have pointed to better lithium responsiveness in a BD subtype characterized by lower psychiatric co-morbidity and more dominant mania-related clinical features.

Human Genetics, University of Bonn, Bonn, DE, Germany; 112Life&Brain Center, Department of Genomics, University of Bonn, Bonn, DE, Germany; 113Epidemiology, Erasmus MC, Rotterdam, Zuid-Holland, the Netherlands; 114Psychiatry, Dokuz Eylul University School of Medicine, Izmir, Turkey; 115Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; 116Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, MA, USA; 117Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, USA; 118Neuroscience and Mental Health, Cardiff University, Cardiff, GB, UK; 119Bioinformatics, University of British Columbia, Vancouver, BC, Canada; 120Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; 121Department of Mathematics, Massachusetts Institute of Technology, Cambridge, MA, USA; 122Department of Psychiatry (UPK), University of Basel, Basel, CH, Switzerland; 123Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, CH, Switzerland; 124Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, DE, Germany; 125Department of Psychiatry, Trinity College Dublin, Dublin, Ireland; 126Psychiatry & Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA; 127Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; 128Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark; 129Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, GB, UK; 130Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, Denmark; 131Institute of Biological Psychiatry, Mental Health Center ScH. Hans, Mental Health Services Capital Region of Denmark, Copenhagen, Denmark; 132iPSYCH, The Lundbeck Foundation Initiative for Psychiatric Research, Copenhagen, Denmark; 133Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia; 134Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine and Ernst Moritz Arndt University Greifswald, Greifswald, Mecklenburg-Vorpommern, DE, Germany; 135Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann- La Roche Ltd, Basel, CH, Switzerland; 136Max Planck Institute of Psychiatry, Munich, DE, Germany; 137Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA; 138Psychiatry & The Behavioral Sciences, University of Southern California, Los Angeles, CA, USA; 139Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA; 140Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 141Informatics Program, Boston Children’s Hospital, Boston, MA, USA; 142Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, GB, UK; 143Department of Endocrinology at Herlev University Hospital, University of Copenhagen, Copenhagen, Denmark; 144Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Lausanne, CH, Switzerland; 145Swiss Institute of Bioinformatics, Lausanne, CH, Switzerland; 146Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, GB, UK; 147Mental Health, NHS 24, Glasgow, GB, UK; 148Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, DE, Germany; 149Statistics, University of Oxford, Oxford, GB, UK; 150Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA; 151School of Psychology and Counseling, Queensland University of Technology, Brisbane, QLD, Australia; 152Child and Youth Mental Health Service, Children’s Health Queensland Hospital and Health Service, South Brisbane, QLD, Australia; 153Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia; 154Estonian Genome Center, University of Tartu, Tartu, Estonia; 155Medical Genetics, University of British Columbia, Vancouver, BC, Canada; 156Statistics, University of British Columbia, Vancouver, BC, Canada; 157DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE, Germany; 158Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE, Germany; 159Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia; 160Humus, Reykjavik, Iceland; 161MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, GB, UK; 162Virginia Institute for Psychiatric & Behavioral
Genetics, Virginia Commonwealth University, Richmond, VA, USA; 163Clinical Genetics, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; 164Complex Trait Genetics, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; 165Solid Biosciences, Boston, MA, USA; 166Department of Psychiatry, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA; 167Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Center for Biomedical Research, University of Granada, Granada, Spain; 168Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; 169Department of Psychiatry and Psychotherapy, Medical Center of the University of Munich, Campus Innenstadt, Munich, DE, Germany; 170Institute of Psychiatric Phenomics and Genomics (IPPPG), Medical Center of the University of Munich, Campus Innenstadt, Munich, DE, Germany; 171Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA; 172Behavioral Health Services, Kaiser Permanente Washington, Seattle, WA, USA; 173Faculty of Medicine, Department of Psychiatry, University of Iceland, Reykjavik, IS, Iceland; 174School of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia; 175Institute of Health and Wellbeing, University of Glasgow, Glasgow, GB, UK; 176deCODE Genetics / Amgen, Reykjavik, Iceland; 177College of Biomedical and Life Sciences, Cardiff University, Cardiff, GB, UK; 178Institute of Epidemiology and Social Medicine, University of Münster, Münster, Nordrhein-Westfalen, DE, Germany; 179Institute for Community Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE, Germany; 180Department of Psychiatry, University of California, San Diego, San Diego, CA, USA; 181KG Jebsen Centre for Psychosis Research, Norway Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; 182Medical Genetics Section, CGEM, IGMM, University of Edinburgh, Edinburgh, GB, UK; 183Clinical Neurosciences, University of Cambridge, Cambridge, GB, UK; 184Internal Medicine, Erasmus MC, Rotterdam, Zuid-Holland, the Netherlands; 185Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery & Translational Medicine Area, Roche Innovation Center Basel, F. Hoffmann- La Roche Ltd, Basel, CH, Switzerland; 186Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE, Germany; 187Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands; 188Virginia Institute of Psychiatric & Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA; 189Computational Sciences Center of Emphasis, Pfizer Global Research and Development, Cambridge, MA, USA; 190Institute for Molecular Bioscience; Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia; 191Department of Psychiatry, University of Münster, Münster, Nordrhein-Westfalen, DE, Germany; 192Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, CH, Switzerland; 193Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, DE, Germany; 194Amsterdam Public Health Institute, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; 195Centre for Integrative Biology, Università degli Studi di Trento, Trento, Trentino-Alto Adige, Italy; 196Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, DE, Germany; 197Psychiatry, Kaiser Permanente Northern California, San Francisco, CA, USA; 198Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, GB, UK; 199Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 200Centre for Addiction and Mental Health, Toronto, ON, Canada; 201Division of Psychiatry, University College London, London, GB, UK; 202Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, USA; 203Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia; 204Psychosis Research Unit, Aarhus University Hospital, Risskov, Aarhus, Denmark; 205University of Liverpool, Liverpool, GB, UK; 206Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; 207Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, CT, USA; 208Psychiatry, Harvard Medical School, Boston, MA, USA; 209Psychiatry, University of Iowa, Iowa City, IA, USA;
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA; 211Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Niedersachsen, DE, Germany; 212Human Genetics Branch, NIMH Division of Intramural Research Programs, Bethesda, MD, USA; 213Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 214Child and Adolescent Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, the Netherlands; 215Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, the Netherlands; 216Psychiatry, Dalhousie University, Halifax, NS, Canada; 217Division of Epidemiology, New York State Psychiatric Institute, New York, NY, USA; 218Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 219Department of Medical & Molecular Genetics, King’s College London, London, GB, UK; 220Psychiatry & Behavioral Sciences, Stanford University, Stanford, CA, USA; 221NIHR BRC for Mental Health, King’s College London, London, GB, UK; 222Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 223Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Funding ATA received a Postgraduate Research Scholarship support from the University of Adelaide through the Adelaide Scholarship International (ASI) program. We thank 23andMe, Inc. staffs for giving us the permission to utilize GWAS summary data for depression which was included as part of the Psychiatric Genomics Consortium (PGC) study. The primary sources of funding were the Deutsche Forschungsgemeinschaft (DFG; grant no. RI 908/7–1; grant FOR2107, RI 908/11–1 to MR, NO246/10–1 to MMN, WI3429/3–1 to SHW) and the Intramural Research Program of the National Institute of Mental Health (ZIA-MH00284311; ClinicalTrials.gov identifier: NCT00001174). The genotyping was in part funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (grants awarded to TGS, MR, and MMN). Some data and biomaterials were collected as part of eleven projects (Study 40) that participated in the National Institute of Mental Health (NIMH) Bipolar Disorder Genetics Initiative. From 2003–2007, the Principal Investigators and Co-Investigators were: Indiana University, Indianapolis, IN, R01 MH59545, John Nurnberger, M.D., Ph.D., Marvin J. Miller, M.D., Elizabeth S. Bowman, M.D., N. Leela Rau, M.D., P. Ryan Moe, M.D., Nalini Samavedy, M.D., Rif El-Mallakh, M.D. (at University of Louisville), Husseini Manji, M.D. (at Johnson and Johnson), Debra A.Glitz, M.D. (atWayne State University), Eric T. Meyer, Ph.D., M.S. (at Oxford University, UK), Carrie Smiley, R.N., Tatiana Foroud, Ph.D., Leah Flury, M.S., Danielle M. Dick, Ph.D. (at Virginia Commonwealth University), Howard Edenberg, Ph.D.;Washington University, St. Louis, MO, R01 MH59534, John Rice, Ph.D., Theodore Reich, M.D., Allison Goate, Ph.D., Laura Bierut, M.D.KO2 DA21237; Johns Hopkins University, Baltimore, M.D., R01 MH59533, Melvin McInnis, M.D., JRD, M.D., Dean F. MacKinnon, M.D., FMM, M.D., JBP, M.D., PPZ, Ph.D., Dimitrios Avramopoulos, and Jennifer Payne; University of Pennsylvania, PA, R01 MH59553, Wade Berrettini, M.D., Ph.D.; University of California at San Francisco, CA, R01 MH60068, William Byerley, M. D., and Sophia Vinogradov, M.D.; University of Iowa, IA, R01 MH59548, William Coryell, M.D., and Raymond Crowe, M.D.; University of Chicago, IL, R01 MH59535, Elliot Gershon, M.D., Judith Badner, Ph.D., Francis McMahon, M.D., Chunyu Liu, Ph.D., Alan Sanders, M.D., Maria Caserta, Steven Dinwiddie, M.D., Tu Nguyen, Donna Harakal; University of California at San Diego, CA, R01 MH59567, JK, M.D., Rebecca McKinney, B.A.; Rush University, IL, R01 MH59556, William Scheftner, M.D., Howard M. Kravitz, D.O., M.P.H., Diana Marta, B.S., Annette Vaughan-Brown, M.S.N., R.N., and Laurie Bederow, M.A.; NIMH Intramural Research Program, Bethesda, MD, 1201MH002810-01, FJM, M.D., JK, Psy.D., Sevilla Detera- Wadleigh, Ph.D., Lisa Austin, Ph.D., Dennis L. Murphy, M.D.; Howard University, William B. Lawson, M.D., Ph.D., Evarista Nwulia, M.D., and Maria Hipolito, M.D. This work was supported by the NIH grants P50CA89392 from the National Cancer Institute and 5K02DA012123from the National Institute of Drug Abuse. The Canadian part of the study was supported by the Canadian Institutes of Health Research to MA grant #64410 to MA. Collection and phenotyping of the Australian UNSW sample, by PBM, PRS, JMF and AW, was funded by an Australian NHMRC Program Grant (No.1037196), with personnel supported by NHMRC project grants (Nos. 1063960, 1066177) and the Janette Mary O’Neil Research Fellowship to JMF. The
collection of the Barcelona sample was supported by the Centro de Investigación en Red de Salud Mental (CIBERSAM), IDIBAPS, the CERCA Programme / Generalitat de Catalunya, Miguel Servet II and Instituto de Salud Carlos III (grant numbers PI080247, PI1200906, PI12/00018, 2017 SGR 1577 and 2017 SGR 1365). Dr FC was funded by unrestricted funding from CIBERSAM and “Secretaria d’Universitats i Recerca del Departament d’ Economia i Coneixement (2017 SGR 134), Generalitat de Catalunya (Government of Catalonia). The Swedish Research Council, the Stockholm County Council, Karolinska Institutet and the Söderström- Königska Foundation supported this research through grants awarded to LB, LF, CL and MS. The collection of the Geneva sample was supported by the Swiss National Foundation (grants Synapsy 51NF40- 158776 and 32003B-125469). The work by the French group was supported by INSERM (Institut National de la Santé et de la Recherche Médicale); AP-HP (Assistance Publique des Hôpitaux de Paris); the Fondation FondaMental (RTRS Santé Mentale) and the labex Bio-PSY (Investissements d’Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02). The German Research Foundation (DFG, grant FOR2107 DA1151/5-1 and DA1151/5–2 to UD; SFBTRR58, Project C09 and Z02 to UD), and the Interdisciplinary Center for Clinical Research (IZKF) of the Medical Faculty of the University of Münster (grant Dan3/012/17 to UD) supported this work. The collection of the Romanian sample was supported by U.E.F.I.S.C.D.I., Romania, grant awarded to MG-S. The collection of the Czech sample was supported by the project No. LO1611 with a financial support from the MEYS under the NPU I program and by the Czech Science Foundation, grant No. 17-07070S.

References